Ligand Pharmaceuticals (LGND) Assets Average (2011 - 2026)

Ligand Pharmaceuticals has disclosed Assets Average across 16 years of filings, most recently posting $1.5 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $1.5 billion, up 67.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 67.43% YoY), and the FY2025 annual result was $1.3 billion, up 44.73% from the prior year.
• Assets Average came in at $1.5 billion for Q1 2026 at Ligand Pharmaceuticals, up from $1.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.5 billion in Q1 2026 to a low of $763.7 million in Q3 2023.
• The 5-year median for Assets Average is $923.6 million (2025), against an average of $1.0 billion.
• Across the five-year window, Assets Average slumped 34.5% in 2023 and soared 67.43% in 2026, its largest moves.
• Ligand Pharmaceuticals' Assets Average stood at $906.6 million in 2022, then dropped by 14.16% to $778.2 million in 2023, then climbed by 21.86% to $948.3 million in 2024, then surged by 60.15% to $1.5 billion in 2025, then grew by 1.82% to $1.5 billion in 2026.
• The last three Assets Average figures came in at $1.5 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.